Werewolf Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 27, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 27, 2026
HOWL$0.97-4.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
(amounts in thousands, except share amounts)
| Common Stock · Additional Paid-in Capital · Accumulated Deficit · Total Stockholders’ Equity | |||||
|---|---|---|---|---|---|
| Shares · Amount | |||||
| Balance at December 31, 2023 | 39,107,048 | $4 | $455,443 | $(344,073) | $111,374 |
| Issuance of common stock from at the market offering, net of issuance costs of $1,283 | 5,272,538 | 1 | 23,527 | — | 23,528 |
| Issuance of common stock, net | 430,349 | — | 142 | — | 142 |
| Stock-based compensation expense | — | — | 8,826 | — | 8,826 |
| Stock option exercises | 17,224 | — | 35 | — | 35 |
| Net loss | — | — | — | (70,515) | (70,515) |
| Balance at December 31, 2024 | 44,827,159 | 5 | 487,973 | (414,588) | 73,390 |
| Issuance of common stock from at the market offering, net of issuance costs of $534 | 3,626,701 | — | 5,903 | — | 5,903 |
| Issuance of common stock, net | 142,957 | — | 89 | — | 89 |
| Stock-based compensation expense | — | — | 6,245 | — | 6,245 |
| Net loss | — | — | — | (60,822) | (60,822) |
| Balance at December 31, 2025 | 48,596,817 | $5 | $500,210 | $(475,410) | $24,805 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.